{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T03:38:38Z","timestamp":1767843518657,"version":"3.49.0"},"reference-count":53,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2019.10929","type":"journal-article","created":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T11:25:43Z","timestamp":1569583543000},"source":"Crossref","is-referenced-by-count":4,"title":["High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: A report of the Polish Myeloma Study Group"],"prefix":"10.3892","author":[{"given":"Iwona","family":"Hus","sequence":"first","affiliation":[{"name":"Department of Clinical Transplantology, Medical University of Lublin, 20-081 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Ma\u0144ko","sequence":"additional","affiliation":[{"name":"Department of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, 20-081 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dariusz","family":"Jawniak","sequence":"additional","affiliation":[{"name":"Department of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, 20-081 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Artur","family":"Jurczyszyn","sequence":"additional","affiliation":[{"name":"Department of Hematology, Collegium Medicum, Jagiellonian University, 30\u2011051 Cracow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grzegorz","family":"Charli\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Hematology, Specialist Muncipial Hospital, 87\u2011100 Torun, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Poniewierska\u2011Jasak","sequence":"additional","affiliation":[{"name":"Department of Hematology, Holycross Cancer Center, 25\u2011734 Kielce, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lidia","family":"Usnarska\u2011Zubkiewicz","sequence":"additional","affiliation":[{"name":"Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, 50\u2011367 Wroclaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mateusz","family":"Sawicki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, 50\u2011367 Wroclaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Druzd\u2011Sitek","sequence":"additional","affiliation":[{"name":"Department of Lymphoid Malignancies, Institute of Oncology, 02\u2011781 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina","family":"\u015awiderska","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Hospital in Zielona G\ufffdra, 65\u2011046 Zielona G\ufffdra, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Kopi\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, Medical University of Silesia, 40\u2011032 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Grz\u0105\u015bko","sequence":"additional","affiliation":[{"name":"Department of Hematology, St. John of Dukla Lublin Region Cancer Center, 20\u2011090 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u0142gorzata","family":"Ra\u017any","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ludwik Rydygier Memorial Specialized Hospital, 31\u2011826 Cracow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"W\u0119d\u0142owska","sequence":"additional","affiliation":[{"name":"Department of Hematology and Transplantology, Medical University of Gdansk, 80\u2011211 Gdansk, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksander","family":"Perzy\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institute of Hematology and Transfusion Medicine, 00\u2011791 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Ga\u0142\u0105zka","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institute of Hematology and Transfusion Medicine, 00\u2011791 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominik","family":"Dytfeld","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, 60\u2011569 Poznan, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadeusz","family":"Kubicki","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, 60\u2011569 Poznan, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Rodzaj","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ludwik Rydygier Memorial Specialized Hospital, 31\u2011826 Cracow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Waszczuk\u2011Gajda","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Internal Medicine, Medical University of Warsaw, 02\u2011097 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Drozd\u2011Soko\u0142owska","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Internal Medicine, Medical University of Warsaw, 02\u2011097 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart\u0142omiej","family":"Pog\u0142\ufffddek","sequence":"additional","affiliation":[{"name":"Department of Oncologic Hematology, Specialist Hospital, 36\u2011200 Brzoz\ufffdw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Pasternak","sequence":"additional","affiliation":[{"name":"Department of Hematology, Independent Public Health Care of Ministry of The Interior and Administration, 10\u2011228 Olsztyn, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"D\u0142ugosz\u2011Danecka","sequence":"additional","affiliation":[{"name":"Department of Hematology, Collegium Medicum, Jagiellonian University, 30\u2011051 Cracow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Szymczyk","sequence":"additional","affiliation":[{"name":"Department of Clinical Transplantology, Medical University of Lublin, 20-081 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Dmoszy\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Clinical Transplantology, Medical University of Lublin, 20-081 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2019,9,27]]},"reference":[{"key":"key20200714092142_b1-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","article-title":"Multiple myeloma: ESMO Clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Moreau","year":"2017","journal-title":"Ann Oncol"},{"key":"key20200714092142_b2-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"4696","DOI":"10.1182\/blood-2010-10-300970","article-title":"Consensus recommendations for risk stratification in multiple myeloma: Report of the International Myeloma workshop consensus panel 2","volume":"117","author":"Munshi","year":"2011","journal-title":"Blood"},{"key":"key20200714092142_b3-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1200\/JCO.2011.37.8919","article-title":"The 39th David A. Karnofsky Lecture: Bench-to-bedside translation of targeted therapies in multiple myeloma","volume":"30","author":"Anderson","year":"2012","journal-title":"J Clin Oncol"},{"key":"key20200714092142_b4-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"key20200714092142_b5-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"230","DOI":"10.6004\/jnccn.2017.0023","article-title":"Multiple myeloma, version 3.2017, NCCN clinical practice guidelines in oncology","volume":"15","author":"Kumar","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"key20200714092142_b6-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.blre.2015.06.001","article-title":"Treatment for patients with newly diagnosed multiple myeloma in 2015","volume":"29","author":"Mateos","year":"2015","journal-title":"Blood Rev"},{"key":"key20200714092142_b7-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1002\/ajh.24402","article-title":"Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Am J Hematol"},{"key":"key20200714092142_b8-ol-0-0-10929","first-page":"159","article-title":"Recommendations of polish myeloma group concerning diagnosis and therapy of multiple myeloma and other plasmacytic dyscrasias for 2015","volume":"46","author":"Dmoszynska","year":"2015","journal-title":"Acta Hematol Pol"},{"key":"key20200714092142_b9-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma","volume":"23","author":"Kyle","year":"2009","journal-title":"Leukemia"},{"key":"key20200714092142_b10-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20200714092142_b11-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: A report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"key20200714092142_b12-ol-0-0-10929","first-page":"719","article-title":"The role of high-dose melphalan and autologous stem cell transplant in the rapidly evolving era of modern multiple myeloma therapy","volume":"14","author":"Voorhees","year":"2016","journal-title":"Clin Adv Hematol Oncol"},{"key":"key20200714092142_b13-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.hemonc.2017.05.005","article-title":"Recent advances in understanding multiple myeloma","volume":"10","author":"Hari","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"key20200714092142_b14-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","article-title":"Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: A randomised phase 3 study","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"key":"key20200714092142_b15-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"5752","DOI":"10.1182\/blood-2011-05-355081","article-title":"Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma","volume":"118","author":"Moreau","year":"2011","journal-title":"Blood"},{"key":"key20200714092142_b16-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1182\/blood-2016-01-693580","article-title":"VTD is superior to VCD prior to intensive therapy in multiple myeloma: Results of the prospective IFM2013-04 trial","volume":"127","author":"Moreau","year":"2016","journal-title":"Blood"},{"key":"key20200714092142_b17-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): A randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"key":"key20200714092142_b18-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1007\/s00277-012-1520-4","article-title":"(Bortezomib plus lenalidomide\/thalidomide)-vs. (bortezomib or lenalidomide\/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: A meta-analysis of randomized controlled trials","volume":"91","author":"Wang","year":"2012","journal-title":"Ann Hematol"},{"key":"key20200714092142_b19-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/joim.12590","article-title":"Modern multiple myeloma therapy: Deep, sustained treatment response and good clinical outcomes","volume":"281","author":"Landgren","year":"2017","journal-title":"J Intern Med"},{"key":"key20200714092142_b20-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.leukres.2014.06.009","article-title":"Bortezomib-thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: A meta-analysis of phase III randomized controlled trials","volume":"38","author":"Huang","year":"2014","journal-title":"Leuk Res"},{"key":"key20200714092142_b21-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1200\/JCO.2011.39.5137","article-title":"Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma","volume":"31","author":"Ludwig","year":"2013","journal-title":"J Clin Oncol"},{"key":"key20200714092142_b22-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","article-title":"Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: A randomized phase 3 PETHEMA\/GEM study","volume":"120","author":"Rosinol","year":"2012","journal-title":"Blood"},{"key":"key20200714092142_b23-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1038\/leu.2015.274","article-title":"Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma","volume":"29","author":"Cavo","year":"2015","journal-title":"Leukemia"},{"key":"key20200714092142_b24-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"4630","DOI":"10.1200\/JCO.2010.28.3945","article-title":"Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p)","volume":"28","author":"Avet-Loisseau","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20200714092142_b25-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"4547","DOI":"10.1182\/blood-2011-04-345801","article-title":"Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance","volume":"118","author":"Mateos","year":"2011","journal-title":"Blood"},{"key":"key20200714092142_b26-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/j.1365-2141.2009.07864.x","article-title":"TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3","volume":"147","author":"Shaughnessy","year":"2009","journal-title":"Br J Haematol"},{"key":"key20200714092142_b27-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.exphem.2014.11.004","article-title":"Cytogenetic and clinical marks for defining high-risk myeloma in the context of bortezomib treatment","volume":"43","author":"An","year":"2015","journal-title":"Exp Hematol"},{"key":"key20200714092142_b28-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1182\/blood-2011-09-379164","article-title":"Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p","volume":"119","author":"Neben","year":"2012","journal-title":"Blood"},{"key":"key20200714092142_b29-ol-0-0-10929","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1182\/blood.V126.23.27.27","article-title":"Bortezomib induction and maintenance in patients with newly diagnosed multiple myeloma: Long-term follow-up of the HOVON-65\/GMMG-HD4 trial","volume":"126","author":"Sonneveld","year":"2015","journal-title":"Blood"},{"key":"key20200714092142_b30-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1182\/blood-2010-08-300863","article-title":"Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM2005-01 trial","volume":"117","author":"Moreau","year":"2011","journal-title":"Blood"},{"key":"key20200714092142_b31-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"key":"key20200714092142_b32-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"key":"key20200714092142_b33-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1002\/ajh.23835","article-title":"Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: Clinical and molecular analyses of a phase 3 study","volume":"89","author":"Tacchetti","year":"2014","journal-title":"Am J Hematol"},{"key":"key20200714092142_b34-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/bjh.12946","article-title":"Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD)-based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: A meta-analysis","volume":"166","author":"Leiba","year":"2014","journal-title":"Br J Haematol"},{"key":"key20200714092142_b35-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"key":"key20200714092142_b36-ol-0-0-10929","first-page":"765","article-title":"Real-life experience with bortezomib-based regimens in elderly patients with newly diagnosed multiple myeloma and comorbidities: A Polish retrospective multicenter study","volume":"127","author":"Hus","year":"2017","journal-title":"Pol Arch Intern Med"},{"key":"key20200714092142_b37-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1080\/10428194.2017.1376743","article-title":"Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: Secondary analysis of the phase 3 ENDEAVOR study","volume":"59","author":"Goldschmidt","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"key20200714092142_b38-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"e485","DOI":"10.3324\/haematol.2016.151266","article-title":"Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial","volume":"101","author":"Merz","year":"2016","journal-title":"Haematologica"},{"key":"key20200714092142_b39-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"e0123866","DOI":"10.1371\/journal.pone.0123866","article-title":"Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy","volume":"10","author":"Minarik","year":"2015","journal-title":"PLoS One"},{"key":"key20200714092142_b40-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/bmt.2014.322","article-title":"Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation","volume":"50","author":"Brioli","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"key20200714092142_b41-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1038\/sj.leu.2404801","article-title":"Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma","volume":"21","author":"Kumar","year":"2007","journal-title":"Leukemia"},{"key":"key20200714092142_b42-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1038\/sj.leu.2405100","article-title":"Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma","volume":"22","author":"Paripati","year":"2008","journal-title":"Leukemia"},{"key":"key20200714092142_b43-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1182\/blood-2009-04-205013","article-title":"Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens","volume":"114","author":"Kumar","year":"2009","journal-title":"Blood"},{"key":"key20200714092142_b44-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/leu.2011.308","article-title":"Majority of patients receiving initial therapy with lenalidomide-based regimens can be successfully mobilized with appropriate mobilization strategies","volume":"26","author":"Sinha","year":"2012","journal-title":"Leukemia"},{"key":"key20200714092142_b45-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00277-015-2557-y","article-title":"Increased efficacy of intermediate-dose cytarabine + G-CSF compared to DHAP + G-CSF for stem cell mobilization in patients with lymphoma: An analysis by the polish lymphoma research group","volume":"95","author":"Giebel","year":"2016","journal-title":"Ann Hematol"},{"key":"key20200714092142_b46-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.1182\/blood-2009-03-201053","article-title":"The role of complete response in multiple myeloma","volume":"114","author":"Harousseau","year":"2009","journal-title":"Blood"},{"key":"key20200714092142_b47-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"key":"key20200714092142_b48-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/bmt.2009.176","article-title":"CR represents an early index of potential long survival in multiple myeloma","volume":"45","author":"Wang","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"key20200714092142_b49-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1200\/JCO.2009.25.4250","article-title":"Importance of achieving a complete response in multiple myeloma, and the impact of novel agents","volume":"28","author":"Chanan-Kahn","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20200714092142_b50-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"Single versus double autologous stem-cell transplantation for multiple myeloma","volume":"349","author":"Attal","year":"2003","journal-title":"N Engl J Med"},{"key":"key20200714092142_b51-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1200\/JCO.2006.10.2509","article-title":"Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study","volume":"25","author":"Cavo","year":"2007","journal-title":"J Clin Oncol"},{"key":"key20200714092142_b52-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00277-016-2897-2","article-title":"Comparison of engraftment following different stem cell mobilization modalities in patients with multiple myeloma treated with a uniform induction regimen containing bortezomib, cyclophosphamide and dexamethasone","volume":"96","author":"Benyamini","year":"2017","journal-title":"Ann Hematol"},{"key":"key20200714092142_b53-ol-0-0-10929","doi-asserted-by":"publisher","first-page":"506","DOI":"10.3324\/haematol.2017.178103","article-title":"Outcome and survival of myeloma patients diagnosed 2008\u20132015. Real-world data on 4904 patients from the Swedish Myeloma Registry","volume":"103","author":"Blimark","year":"2018","journal-title":"Haematologica"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T09:58:13Z","timestamp":1594720693000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2019.10929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,27]]},"references-count":53,"URL":"https:\/\/doi.org\/10.3892\/ol.2019.10929","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,27]]}}}